APRIL — Springtime for New IgA Nephropathy Therapy?

IgA nephropathy is the most common primary glomerulonephritis in most of the world. It typically manifests in childhood or young adulthood. Although it has substantial clinical heterogeneity, it has been considered to be a slowly progressive disease1 among patients without risk indicators such as high-grade proteinuria, marked hypertension, and specific biopsy findings. After a risk assessment is performed on the basis of a kidney biopsy (with the use of the Oxford Classification MEST-C score, which is based on the presence of mesangial [M] and endocapillary [E] hypercellularity, segmental sclerosis [S], interstitial fibrosis or tubular atrophy [T], and crescents [C]) and . . .